Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Abstract: The present disclosure is directed to anti-VP1 antibodies, antibody fragments, and their uses for the reducing the likelihood or treatment of polyoma virus infection.

Abstract: Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract: The invention describes new synthetic medical adhesives and films which exploit the key components of natural marine mussel adhesive proteins.

Abstract: A method for implementing mobile relay station is provided. The method includes performing spectrum sensing at least one spectrum sensing entity in a base station, a mobile relay station and a user terminal, sending, by the spectrum sensing entity, the result of spectrum sensing to a spectrum managing entity in the mobile communication system, allocating, by the spectrum managing entity available spectrum to a first link between the mobile relay station and the base station and allocating, by the spectrum managing entity, the available spectrums to a second link between the mobile relay station and the user terminal as working spectrum. The present invention also provides a mobile relay station system. The present invention can solve the problem of capacity bottleneck in the backhaul links and access links in high speed wireless environment.

Abstract: The invention describes new synthetic medical adhesives and films which exploit the key components of natural marine mussel adhesive proteins.

Abstract: A method for positioning a Mobile Station (MS) is provided. The method includes transmitting, by a serving base station of a MS, indication information of a Location Based Services (LBS) zone to the MS receiving, by the MS according to the indication information, a reference signal used for positioning the MS in the LBS zone from a base station of a neighboring cell, wherein the LBS zone is multiplexed with a control information field in N downlink subframes, or with the control information field and a data field in the N downlink subframes, and wherein N is larger than or equal to 1. In the case of restraining interference of a serving cell signal to a neighboring cell signal, the requirements of system resource allocation and Hybrid Automatic Repeat Request (HARQ) timing synchronization can also be satisfied.

Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.

Abstract: The invention describes families of compounds that utilize multihydroxyl phenyl groups to provide adhesive properties. Selection of the multihydroxy phenyl group along with linkers or linking groups and the linkages between the linkers or linking groups with polyalkylene oxides, provides materials that can be engineered to afford controllable curing time, biodegradation and/or swelling.

Abstract: The invention relates generally to thin-film adhesive materials suitable for various applications. In particular, the present invention provides pliable viscoelastic thin-films configured to form strong water-resistant adhesive bonds to various surface types.

Abstract: An endovascular device for occluding a vascular aneurysm is disclosed. The device includes a polymeric shell member that, in one embodiment, may be constructed from a bioactive and biocompatible polyurethane-diol-glycosaminoglycan copolymer, and a biocompatible metallic frame member. The copolymer is sufficiently flexible and strong for endovascular delivery into a vascular aneurysm and for use as a polymeric shell for receiving the biocompatible metallic frame member. The biometallic frame member may include one or more components constructed from a NiTi alloy.

Abstract: An endovascular device for occluding a vascular aneurysm is disclosed. The device includes a polymeric shell member that, in one embodiment, may be constructed from a bioactive and biocompatible polyurethane-diol-glycosaminoglycan copolymer, and a liquid embolic agent. The copolymer is sufficiently flexible and strong for endovascular delivery into a vascular aneurysm and for use as a polymeric shell for receiving the liquid embolic agent. Upon activation inside of the polymeric shell within the aneurysm, the liquid embolic agent solidifies enabling biological isolation of the aneurysm and improved patient outcomes.